Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
Open Access
- 16 July 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (7) , 1963
Abstract
Nonalcoholic fatty liver disease (NAFLD) has become globally prevalent and is the leading cause of chronic liver disease. Although NAFLD is reversible without medical intervention in the early stage, the condition could be sequentially worsened to nonalcoholic steatohepatitis (NASH) and, eventually, cirrhosis and hepatic cancer. The progression of NAFLD is related to various factors such as genetics, pre-disposed metabolic disorders, and immunologic factors. Thankfully, to date, there have been accumulating research efforts and, as a result, different classes of potent drug candidates have been discovered. In addition, there have also been various attempts to explore pharmaceutical strategies to improve the druggability of drug candidates. In this review, we provided a brief overview of the drug candidates that have undergone clinical trials. In the latter part, strategies for developing better drugs are discussed.Keywords
All Related Versions
Funding Information
- National Research Foundation of Korea (NRF-2021R1F1A1058214, NRF-2021R1F1A1064206, NRF-2018R1D1A1A02047809, NRF-2018R1D1A1B07048818, RS-2023-00219399)
- National Research Foundation of Korea (NRF-2021R1F1A1058214, NRF-2021R1F1A1064206, NRF-2018R1D1A1A02047809, NRF-2018R1D1A1B07048818, RS-2023-00219399)
- Basic Science Research Program through the National Research Foundation of Korea (NRF-2021R1F1A1058214, NRF-2021R1F1A1064206, NRF-2018R1D1A1A02047809, NRF-2018R1D1A1B07048818, RS-2023-00219399)
This publication has 175 references indexed in Scilit:
- Ageing Fxr Deficient Mice Develop Increased Energy Expenditure, Improved Glucose Control and Liver Damage Resembling NASHPLOS ONE, 2013
- The TGR5 receptor mediates bile acid–induced itch and analgesiaJournal of Clinical Investigation, 2013
- Tissue-specific function of farnesoid X receptor in liver and intestinePharmacological Research, 2011
- The metabolic actions of glucagon revisitedNature Reviews Endocrinology, 2010
- Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 AgonistMolecular Pharmacology, 2010
- Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based MechanismsMolecular Therapy, 2010
- Factors Affecting the Clearance and Biodistribution of Polymeric NanoparticlesMolecular Pharmaceutics, 2008
- Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21Journal of Biological Chemistry, 2007
- Albumin Binding to FcRn: Distinct from the FcRn−IgG InteractionBiochemistry, 2006
- FGF-21 as a novel metabolic regulatorJournal of Clinical Investigation, 2005